MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Oxymetazoline

Selected References:

  • Arendt KW, et al. 2011. Topical vasoconstrictor use for nasal intubation during pregnancy complicated by cardiomyopathy and preeclampsia. Int J Obstet Anesth. 20(3):246-9.
  • Aselton P, et al. 1985. First-trimester drug use and congenital disorders. Obstet Gynecol 65:451-455, 1985.
  • Baxi LV, et al. 1985. Fetal heart rate changes following maternal administration of a nasal decongestant. Am J Obstet Gynecol. 153:799-800.
  • Jick H, et al. 1981. First-trimester drug use and congenital disorders. JAMA 246:343-346.
  • Mazzotta P, et al. 1999. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf. 20(4):361-75.
  • Menezes GA, et al. 2016. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. J Obstet Gynaecol Res. 42(8):1016-20.
  • Rayburn WF, et al. 1990. Uterine and fetal Doppler flow changes from a single dose of a long-acting intranasal decongestant. Obstet Gynecol. 76:180-2.
  • Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 178(2):198-208.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.